Use of nadph oxidase inhibitors for the manufacture of a medicament for prevention of atherosclerosis
CA 2238098 C · Owner: Holland, James A. · Inventors: Holland, James A.; Johnson, David K.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method for the prevention and treatment of atherosclerosis and its related diseases in mammals, in which an NADPH oxidase inhibitor is administered is , provided. The NADPH oxidase inhibitor prevents the production of reactive oxygen species upon exposure of endothetial cells to atherogenic LDL levels thus resulting in decreased endocytosis and vascular hyperpermeability. Preferred NADPH oxidase inhibitors are of formula (I). Additionally there is , provided a diagnostic method for predicting risk of a human patient to atherosclerotic-related diseases.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 27, 1996 and granted January 30, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 27, 2016.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 27, 2018.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.